Nxera Pharma Posts EPS -$0.54, $29.3M Revenue Shortfall
Nxera Pharma Co., Ltd. reported Q4 EPS of -$0.54, missing estimates by $1.01 and recording $49.6 million revenue versus the $78.9 million forecast. The company’s current ratio of 3.14 underscores strong liquidity despite a negative P/E of -12.22 and cash flow challenges.
1. Q4 Financial Performance
Nxera Pharma reported fourth-quarter EPS of -$0.54, missing the $0.47 consensus by $1.01, and posted revenue of $49.6 million, falling $29.3 million short of the $78.9 million estimate.
2. Liquidity and Valuation Ratios
The company’s current ratio remains strong at 3.14, suggesting solid coverage of short-term obligations, while a negative P/E ratio of -12.22 and price-to-sales ratio of 2.62 reflect profitability and valuation pressures.
3. Cash Flow and Debt Levels
An enterprise value to operating cash flow ratio of -8.15 highlights ongoing cash flow generation challenges, and a debt-to-equity ratio near 0.96 indicates moderate leverage that may constrain future investment without improved earnings.